IMMEDIATE RESPONSE TO NEOADJUVANT CHEMOTHERAPY INCLUDING CAPECITABINE AND LONG-TERM TREATMENT OUTCOMES OF OPERABLE BREAST CANCER
https://doi.org/10.21294/1814-4861-2016-15-3-37-42
Abstract
The present study was undertaken to determine the relationship between tumor response to neoadjuvant chemotherapy including capecitabine and long-term treatment outcomes in patients with operable breast cancer. material and methods. The study included 139 patients with stage T2-3N0-2M0 breast cancer, who received 2-4 courses of neoadjuvant chemotherapy with the FAC and САХ regimens. Immediate response was assessed using the RECIST criteria. Long-term treatment outcomes and metastasis-free survival rates were evaluated using the Kaplan-Meier method. Results. By assessing the relationship between long-term treatment outcomes and the immediate response to adjuvant chemotherapy with capecitabine, we identified the group of patients with tumor regression ≥ 80%, who had the 7-year metastasis-free survival rates similar to those observed in patients with pathologic complete response. Such factors as the primary tumor size, regional tumor spread, receptor status of tumor tissue and the number of chemotherapy courses were found to have no impact on the frequency of hematogenous metastasis. Conclusion. The results obtained indicate that ≥ 80% tumor regression after neoadjuvanch chemotherapy including capecitabine can be considered as a predictive parameter for assessing metastasis-free survival in patients with operable breast cancer.
About the Authors
E. M. Slonimskaya
Tomsk Cancer Research Institute, Siberian State Medical Univesity
Russian Federation
MD, DSс, Professor, Head of General Oncology Department
Russian Federation
MD, DSс, Professor, Head of General Oncology Department
N. A. Tarabanovskaya
Tomsk Cancer Research Institute
Russian Federation
MD, PhD, Junior Researcher, General Oncology Department
Russian Federation
MD, PhD, Junior Researcher, General Oncology Department
A. V. Doroshenko
Tomsk Cancer Research Institute
Russian Federation
MD, PhD, Researcher, General Oncology Department
Russian Federation
MD, PhD, Researcher, General Oncology Department
S. V. Patalyak
Tomsk Cancer Research Institute, Siberian State Medical Univesity
Russian Federation
MD, PhD, Junior Researcher, General Oncology Department
Russian Federation
MD, PhD, Junior Researcher, General Oncology Department
References
1. Slonimskaja E.M., Bragina O.V., Tarabanovskaja N.A., Doroshenko A.V., Garbukov E.Ju. Experience in the use of capecitabine in the neoadjuvant chemotherapy for breast cancer // Sovremennaja onkologija. 2012. № 4. P. 22–25. [in Russian]
2. Bonnefoi H., Litière S., Piccart M., MacGrogan G., Fumoleau P., Brain E., Petit T., Rouanet P., Jassem J., Moldovan C., Bodmer A., Zaman K., Cufer T., Campone M., Luporsi E., Malmström P., Werutsky G., Bogaerts J., Bergh J., Cameron D.A. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial // Ann. Oncol. 2014. Vol. 25 (6). Р. 1128–1136. doi: 10.1093/annonc/mdu118.
3. Hatzis C., Symmans W.F., Zhang Y., Gould R., Moulder S., Hunt K.K., Abu-Khalaf M.M., Hofstatter E., Lannin D.R., Chagpar A.B., Pusztai L. Relationship between complete pathologic response to neoadjuvant chemotherapy and survival in triple negative breast cancer // Clin. Cancer Res. 2016. Vol. 22 (1). P. 26–33. doi: 10.1158/1078-0432.CCR-14-3304.
4. Eremin J., Cowley G., Walker L.G., Murray E., Stovickova M., Eremin O. Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival // Springerplus. 2015. Vol. 4. P. 9. doi: 10.1186/2193-1801-4-9.
5. Kaufmann M., Von Minckwitz G., Mamounas E.P., Cameron D., Carey L.A., Cristofanilli M., Denkert C., Eiermann W., Gnant M., Harris J.R., Karn T., Liedtke C., Mauri D., Rouzier R., Ruckhaeberle E., Semiglazov V., Symmans W.F., Tutt A., Pusztai L. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer // Ann. Surg. Oncol. 2012. Vol. 19 (5). Р. 1508–1516. doi: 10.1245/s10434-011-2108-2.
6. Luangdilok S., Samarnthai N., Korphaisarn K. Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients // J. Breast Cancer. 2014. Vol. 17 (4). Р. 376–385. doi: 10.4048/jbc.2014.17.4.376.
7. Miller M., Ottesen R.A., Niland J.C., Kruper L., Chen S.L., Vito C. Tumor response ratio predicts overall survival in breast cancer patients treated with neoadjuvant chemotherapy // Ann. Surg. Oncol. 2014. Vol. 21 (10). P. 3317–3323. doi: 10.1245/s10434-014-3922-0.
8. Steger G.G., Greil R., Lang A., Rudas M., Fitzal F., Mlineritsch B., Hartmann B. L., Bartsch R., Melbinger E., Hubalek M., Stoeger H., Dubsky P., Ressler S., Petzer A.L., Singer C. F., Muss C., Jakesz R., Gampenrieder S.P., Zielinski C.C., Fesl C., Gnant M. Epirubicine and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24) // Ann. Oncol. 2014. Vol. 25 (2). P. 366–371. doi: 10.1093/annonc/mdt508.
9. Symmans W.F., Peintinger F., Hatzis C., Rajan R., Kuerer H., Valero V., Assad L., Poniecka A., Hennessy B., Green M., Buzdar A.U., Singletary S.E., Hortobagyi G.N., Pusztai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy // J. Clin. Oncol. 2007. Vol. 25 (28). P. 4414–4422.
10. Teshome M., Hunt K.K. Neoadjuvant Therapy in the Treatment of Breast Cancer // Surg. Oncol. Clin. N. Am. 2014. Vol. 23 (3). Р. 505–523. doi: 10.1016/j.soc.2014.03.006
11. Haddad T.C., Goetz M.P. Landscape of neoadjuvant therapy for breast cancer // Ann. Surg. Oncol. 2015. Vol. 22 (5). P. 1408–1415. doi: 10.1245/s10434-015-4405-7.
12. Rapoport B.L., Demetriou G.S., Moodley S.D., Benn C.A. When and how do I use neoadjuvant chemotherapy for breast cancer? // Curr. Treat. Option. 2014. Vol. 15 (1). Р. 86–98. doi: 10.1007/s11864-013-0266-0.
13. Rastogi P., Geyer C.E. Jr., Mamounas E.P., DeMichele A. Drug development: neoadjuvant opportunities in breast cancer // Am. Soc. Clin. Oncol. Educ. Book. 2013. P. 73–79. doi: 10.1200/EdBook_AM.2013.33.73.
14.
Review
For citations:
Slonimskaya E.M., Tarabanovskaya N.A., Doroshenko A.V., Patalyak S.V. IMMEDIATE RESPONSE TO NEOADJUVANT CHEMOTHERAPY INCLUDING CAPECITABINE AND LONG-TERM TREATMENT OUTCOMES OF OPERABLE BREAST CANCER. Siberian journal of oncology. 2016;15(3):37-42. (In Russ.) https://doi.org/10.21294/1814-4861-2016-15-3-37-42
Views:
2040
Email this article 
